• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Human pharmacological studies of a defined low molecular weight heparin fraction (Fragmin) evidence for a simultaneous inhibition of factor Xa and IIa (thrombin).

作者信息

Andrassy K, Mörike K, Koderisch J, Weber E

机构信息

Department of Nephrology, University Medical Hospital, Heidelberg, FRG.

出版信息

Thromb Res. 1988 Mar 15;49(6):601-11. doi: 10.1016/0049-3848(88)90257-5.

DOI:10.1016/0049-3848(88)90257-5
PMID:3164530
Abstract

The effect of a low molecular weight heparin (Fragmin) (20-80 U/kg) was studied in 10 healthy male volunteers after intravenous administration. Clotting abnormalities are extensive shortly after injection, lasting for 1-2 hours depending on heparin dosage. Dilute thrombin time, showing a close correlation to anti-F-Xa activity, is as sensitive as anti-F-Xa. The parallel time course of dilute thrombin time and anti-F-Xa activity clearly demonstrates that LMWH has an effect on F-IIa lasting as long as that of F-Xa. After subcutaneous administration clotting abnormalities are only slight with 40-60 U/kg, in contrast to the intravenous study. The platelet system remains unchanged.

摘要

相似文献

1
Human pharmacological studies of a defined low molecular weight heparin fraction (Fragmin) evidence for a simultaneous inhibition of factor Xa and IIa (thrombin).
Thromb Res. 1988 Mar 15;49(6):601-11. doi: 10.1016/0049-3848(88)90257-5.
2
Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.健康志愿者皮下注射175 iu/kg替扎肝素后的抗凝药效学。
Thromb Res. 2001 Feb 15;101(4):243-54. doi: 10.1016/s0049-3848(00)00412-6.
3
A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan.三种低分子量肝素与糖胺聚糖抗凝血作用的交叉比较。
Br J Clin Pharmacol. 1993 Jul;36(1):51-6. doi: 10.1111/j.1365-2125.1993.tb05891.x.
4
Pharmacokinetics of low molecular weight heparins.低分子量肝素的药代动力学
Acta Chir Scand Suppl. 1988;543:65-72.
5
Pharmacokinetics of Clivarin a new low molecular weight heparin in healthy volunteers.新型低分子量肝素克利肝素在健康志愿者体内的药代动力学
Thromb Res. 1994 Jan 15;73(2):95-108. doi: 10.1016/0049-3848(94)90084-1.
6
A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.健康志愿者中三种低分子量肝素(LMWH)与普通肝素(UH)的对比研究。
Thromb Haemost. 1995 Mar;73(3):398-401.
7
Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor.依诺肝素与普通肝素对健康志愿者凝血过程中全血凝血酶原消耗及组织因子途径抑制物释放的比较作用。
Thromb Res. 1993 Mar 1;69(5):443-52. doi: 10.1016/0049-3848(93)90233-e.
8
Clinical pharmacology of a new low molecular weight heparin (Alfa LMWH-Fluxum).一种新型低分子量肝素(阿法低分子量肝素 - 氟克昔明)的临床药理学
Int Angiol. 1988 Jul-Sep;7(3 Suppl):7-18.
9
Anti-IIa and anti-Xa plasma activities after subcutaneous low-dose application of low-molecular-weight heparins to rabbits.对兔皮下低剂量应用低分子量肝素后的抗凝血酶IIa和抗Xa血浆活性。
Haemostasis. 1988;18 Suppl 3:64-8. doi: 10.1159/000215869.
10
Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.单次皮下注射低剂量肝素或低分子量肝素 - 双氢麦角胺组合后的纤溶和抗凝活性。
Thromb Haemost. 1988 Jun 16;59(3):388-91.

引用本文的文献

1
Delivery of low molecular weight heparin for prophylaxis against deep vein thrombosis using a novel, needle-less injection device (J-Tip).使用新型无针注射装置(J-Tip)注射低分子量肝素预防深静脉血栓形成
Ann R Coll Surg Engl. 2000 Nov;82(6):428-31.
2
Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.达肝素:其在预防和治疗血栓栓塞性疾病方面的药理特性及临床疗效的最新进展
Drugs. 2000 Jul;60(1):203-37. doi: 10.2165/00003495-200060010-00010.
3
Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
达肝素钠。其药理学及在预防和治疗血栓栓塞性疾病中的临床应用综述。
Drugs. 1996 Aug;52(2):276-305. doi: 10.2165/00003495-199652020-00011.
4
The possible involvement of platelet activation in endotoxin-induced renal insufficiency in a rabbit model.血小板活化在兔模型内毒素诱导的肾功能不全中的可能作用。
Jpn J Surg. 1991 Sep;21(5):542-6. doi: 10.1007/BF02470992.